A Collaborative Fight Against Ovarian Cancer
Cancer research at the Ovarian Cancer Institute is directed by Chief Research Officer, Dr. John McDonald, at his state-of-the-art laboratory on the campus of the Georgia Institute of Technology in Atlanta. Here, cutting-edge discoveries in molecular cancer biology are combined with Georgia Tech’s strengths in analytical chemistry, computational sciences, and nanotechnology. Because of this collaboration, our support for this laboratory sets us apart from the “traditional cancer research institute.”
To advance cancer research, patients have volunteered to provide medical history information and tissue and serum samples. Because the medical offices are located just a few miles from the lab, samples were collected by Dr. Benedict Benigno, OCI’s founder and CEO, and were immediately flash-frozen and transported to the cancer research laboratory. Due to the pristine tumor samples and the availability of medical histories, the Ovarian Cancer Institute-funded laboratory has established a highly comprehensive ovarian cancer research program that is unique to any other in the U.S. or the world. As a result, the lab supported by the Ovarian Cancer Institute is home to one of the largest tissue and serum banks and ovarian cancer patient-history databases in the world.
The ultimate goal is an early diagnostic test for ovarian cancer and better, more effective treatment plan for those suffering from ovarian cancer.
Ovarian Cancer Institute researchers are having a significant impact in two areas of cancer biology: Diagnostics and Therapeutics.
Diagnostics: Developing an Early-Diagnostic Test for Ovarian Cancer
Since its inception, the cancer research institute has worked to develop an early diagnostic test for ovarian cancer. Such a test would save countless lives and completely change the ovarian cancer forecast. Taking a unique approach to ovarian cancer diagnostics by studying metabolites, Ovarian Cancer Institute-supported researchers have developed an early diagnostic test that is 100% sensitive and specific. Because ovarian cancer Stage I samples are so difficult to come by and this test has been discovered with a small quantity, researchers are working toward acquiring a larger number of Stage I ovarian cancer samples for validation of the test.
Therapeutics: Developing Better Treatments for Ovarian Cancer
Even with accurate diagnostics, the need for cancer treatments will always exist. Most ovarian cancer patients are subject to extensive surgery and chemotherapy delivering as much toxicity to the skin of the elbow as it does to the cancerous tumor. The Ovarian Cancer Institute is dedicated to funding cancer research that develops treatments that are not only more effective, but also less toxic. This includes custom delivery of chemotherapy to tumors, and predicting what chemotherapy each individual would respond to best from the beginning based on the individuals DNA.
To learn more about our cancer research institute; our world renowned CEO and scientists; how to volunteer; or to attend one of our yearly fundraising events, contact the Ovarian Cancer Institute at 404-300-2997, or use our contact form.